Comments
As a non-medicinal answer to the gastrointestinal problems such as diarrhoea, Irritable Bowel Syndrome (IBS) or Inflammatory Bowel Disease (IBD), the Ahmedabad-based Sundyota Numandis has tied up with Italian Probiotical to offer world’s most researched probiotic product, Lactobacillus rhamnosus GG, in Indian market.
As per the pact, Sundyota Numandis procures coated oro-soluble L rhamnosus GG from Probiotical, Italy and manufacture it for the Indian market. Sundyota Numandis markets the product under the brand name of SuperFlora GG. The company has also inked a strategic agreement with pharma major Cipla to market in tandem the same probiotic product. Cipla’s product is named ‘Unobiotics’ and is available as a 1 gram sachet priced at ₹45.
New facility
“Currently, we are getting our product manufactured at Una in Himachal Pradesh through a third party. But we plan to set up our own new formulations facility at Changodar near Ahmedabad, with an investment of about ₹80 crore. The plant will be ready by November-December. We will supply the product to Cipla and they will market it under their brand,” said Dinesh Arora, managing director and CEO, Sundyota Numandis. The proposed manufacturing facility will have capacity to make 51 crore sachets per annum, with additional capacity to make capsules, liquids and tablets.
Lactobacillus rhamnosus GG is meant to support gastro-intestinal health and general well-being in children as well as adults with no adverse effects.
After extensive scientific studies on probiotic, Sundyota Numandis introduced the probiotic in a technologically superior and consumer compliant oro-dispersible powder form which is stable in Indian climate and called as Microbac GG. The sensitivity of L rhamnosus GG does not allow it to survive in climatic conditions of high temperature and humidity , it necessitates a technological advancement to increase its viability and stability.
“Lactobacillus rhamnosus GG is globally the number one choice amongst probiotics. The Indian probiotic market is valued at approximately ₹1000 crore and is growing at a rate of 15 per cent. We will be manufacturing 1 million sachets of Microbac GG every month. In future, we will also introduce L rhamnosus GG in various formulations like drops and capsules,” Arora said.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.